News / Business
Acadia Pharmaceuticals Inc (ACAD) to Release Q4 2007 Earnings Report March 5
Acadia
Pharmaceuticals Inc (NASDAQ:ACAD) will release the fourth quarter earnings
for 2007 on March 5.
A
biopharmaceutical company, Acadia Pharmaceuticals is engaged in the discovery,
development and commercialization of small molecule drugs to treat central
nervous system disorders. The company is
organized into five programs involving clinical development as well as numerous
other programs concerning preclinical development and discovery stages.
The
company’s advanced program has entered Phase III development for ACP-103, which
is to be used to treat Parkinson’s disease psychosis. The company’s Phase II programs focus on
ACP-103 for schizophrenia, ACP-103 for sleep maintenance insomnia and ACP-104
for schizophrenia. The company’s
neuropathic pain program is in Phase II of clinical trials while in
collaboration with Allergan Inc (NYSE:AGN).
For more
Earnings related events or to post your own events, visit:
